Review
doi: 10.1007/978-1-4615-9442-0_24.
Biological actions of prostacyclin and its pharmacological use in platelet studies
- PMID: 3010671
- DOI: 10.1007/978-1-4615-9442-0_24
Item in Clipboard
Review
Biological actions of prostacyclin and its pharmacological use in platelet studies
Adv Exp Med Biol.
1985.
No abstract available
Similar articles
-
Independence of the cyclic AMP-lowering activity of thromboxane A2 from the platelet release reaction.Biochim Biophys Acta. 1979 Jan 29;572(1):95-104. doi: 10.1016/0005-2760(79)90203-0. Biochim Biophys Acta. 1979. PMID: 216409 No abstract available.
-
A pharmacological approach to the inhibition of platelet adhesion and platelet aggregation. Wright-Schulte Lecture.Haemostasis. 1982;12(4):317-36. doi: 10.1159/000214690. Haemostasis. 1982. PMID: 6295896
-
Role of thromboxane A2.Adv Exp Med Biol. 1985;192:293-308. doi: 10.1007/978-1-4615-9442-0_21. Adv Exp Med Biol. 1985. PMID: 2939695 Review. No abstract available.
-
Mode of action of dipyridamole on human platelets.Thromb Res. 1979;16(3-4):367-79. doi: 10.1016/0049-3848(79)90084-7. Thromb Res. 1979. PMID: 229583 No abstract available.
-
Are the vascular complications of diabetes mellitus preceded by an altered thromboxane/prostacyclin plasmatic ratio?Med Hypotheses. 1986 Mar;19(3):229-41. doi: 10.1016/0306-9877(86)90070-8. Med Hypotheses. 1986. PMID: 3007948 Review.
Cited by
-
8th Asian PAD Workshop.Ann Vasc Dis. 2017 Dec 25;10(4):449-458. doi: 10.3400/avd.pad.17-01000. Ann Vasc Dis. 2017. PMID: 29515714 Free PMC article. No abstract available.
-
Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.Br Heart J. 1994 Jan;71(1):7-15. doi: 10.1136/hrt.71.1.7. Br Heart J. 1994. PMID: 8297699 Free PMC article. Clinical Trial.